Home Featured Page 216

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products...

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic...

Editor’s Choice Award 2021-Best Study on Psychedelics and Nature

PT276 – Micah Haskell-Hoehl – Healing, Equity, and Federal Policy

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products...

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic...

Editor’s Choice Award 2021-Best Study on Psychedelics and Nature

PT276 – Micah Haskell-Hoehl – Healing, Equity, and Federal Policy

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY